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• Despite being the wealthiest nation on Earth, the US has one of the highest preterm birth (PTB) rates compared to other developed nations. 1 • Short cervix (SC), defined as cervical length (CL) <25mm on transvaginal sonography, is a common risk factor for PTB (delivery <37 gestational weeks). 2, 3 • SC is diagnosed through serial CL screening (SS), with vaginal progesterone (VP) and cervical cerclage as available treatment options for those diagnosed with SC. 2 • SS may significantly improve public health by reducing PTB.
• To develop a decision analytic model to assess costs and effectiveness of SS+VP and SS+cerclage versus no screening (NS) in preventing PTB among high-risk US women (those with a history of PTB) carrying a singleton gestation.
• Similar effectiveness was observed between SS+VP, SS+cerclage, and NS at both PTB thresholds.
• From a cost-minimization standpoint, SS+VP is the most cost-saving strategy, costing $47,882.
• SS+cerclage was the most effective method, preventing 8,081 more PTBs than NS for additional $43M (0.26% of total costs) in our hypothetical population analysis (Table 1 ).
• For women with SC, SS+VP is less costly and SS+cerclage is more effective compared to NS in preventing recurrent PTB.
• Model is critical to informing US policy because it quantifies costs and PTB reduction of modern practice in high-risk women with SC.
• Future work includes incorporating pessary with updated efficacy data as well as adjunctive 17-OHP use with cerclage.
• Model limited to high-risk women with singleton gestations.
• Pessary is not included as a treatment option for SC.
• PTB probabilities in the cerclage arm do not consider adjunctive 17-OHP use.
This study was unfunded. • Model is most sensitive to variation in: 1) cost of PTB before 35 weeks, 2) 17-OHP cost, and 3) term delivery cost (Figure 2 ).
• On PSA, each SS strategy was more effective than NS at 37 weeks, though only SS+VP was less costly overall ( Figures 3 and 4) .
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